Protein Sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Edman Degradation,Mass Spectrometry), By Application (Academic Institutes & Research Centers,Pharmaceutical & Biotechnology Companies,Others), Regional Insights and Forecast to 2035

Protein Sequencing Market Overview

The global Protein Sequencing Market size is projected to grow from USD 1113.44 million in 2026 to USD 1147.74 million in 2027, reaching USD 1462.52 million by 2035, expanding at a CAGR of 3.08% during the forecast period.

The global Protein Sequencing Market reached an estimated value of USD 2.04 billion in 2024, with North America accounting for nearly 36% of the overall market share. The product segment contributed approximately 81% of the global market in 2023, while services accounted for the remaining 19%. Biotherapeutics represented around 56% of total applications, showing dominance over academic and other end-user segments. Mass spectrometry systems comprised nearly 54% of technology adoption, compared with Edman Degradation at 46%. Rising investments in proteomics research and drug discovery programs fueled demand. The Protein Sequencing Market Report indicates steady growth across pharmaceutical, biotechnology, and academic institutions.

The USA Protein Sequencing Market contributed around 25% of the global market, equivalent to USD 514 million in 2024. The domestic market is characterized by strong pharmaceutical adoption, with biotherapeutics accounting for over 50% of U.S. application share. The product category held above 80% share, led by instruments, kits, and reagents. U.S. academic institutes and research centers contributed nearly 60% of proteomics funding. Mass spectrometry accounted for around 65% of installed equipment, with Edman Degradation making up the remaining 35%. The USA continues to lead global sequencing adoption through advanced laboratory infrastructure and research funding.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 81% product segment in 2023 with 56% biotherapeutics application driving adoption.
• Major Market Restraint: 19% services share in 2023 with 44% of demand outside biotherapeutics underserved.
• Emerging Trends: 36% North America market share, 56% biotherapeutics share, and 12–15% growth in single-molecule sequencing.
• Regional Leadership: North America 36%, Europe 22–25%, Asia-Pacific rising from 15% to 20%, Middle East & Africa at 5–7%.
• Competitive Landscape: Mass spectrometry 54%, Edman Degradation 46%, top two companies holding 25–30% combined.
• Market Segmentation: Products 81%, Services 19%, Biotherapeutics 56%, Academic 45%, Pharma/Biotech 50%, Others 5%.
• Recent Development: New kits improving detection by 20%, U.S. genetic tests tripling from 1,000 to 3,000 within one year.

Protein Sequencing Market Latest Trends

The Protein Sequencing Market Trends emphasize strong growth in high-throughput technologies. In 2023, products dominated with 81% of market share, while services held 19%. Mass spectrometry accounted for 54% of installations, overtaking Edman Degradation at 46%. Academic institutes represented 45% of total consumption, pharmaceutical and biotechnology firms 50%, and others 5%. Biotherapeutics led all applications with 56% of share. North America remained the global leader with 36% of the market, while Asia-Pacific expanded from 15% in 2020 to nearly 20% in 2024. Single-molecule sequencing systems accounted for 12–15% of new purchases. Kits launched in 2024 enhanced amino acid detection by 20% and reduced costs significantly. U.S. demand grew rapidly, with genetic tests increasing from 1,000 in 2021 to 3,000 in 2022. Asia-Pacific laboratories expanded equipment installations by 10% annually, driven by pharmaceutical outsourcing. The Protein Sequencing Market Analysis highlights strong innovation pipelines across proteomics, antibody sequencing, and personalized medicine applications.

Protein Sequencing Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

Pharmaceutical and biotechnology companies held 50% of end-user share in 2023, with biotherapeutics representing 56% of all applications. This expansion directly drives sequencing adoption. Products accounted for 81% of purchases, emphasizing instruments, reagents, and consumables. North America contributed 36% of total global share, and U.S. demand was valued at USD 514 million. Mass spectrometry held 54% of installations, supporting faster sequencing for antibody development and drug discovery. Between 2021 and 2022, genetic tests in the U.S. rose from 1,000 to 3,000, reflecting increasing pharmaceutical reliance on protein sequencing. Single-molecule sequencing accounted for 15% of new adoption, enabling novel drug development.

RESTRAINT

"Limited service segment uptake."

The services segment accounted for only 19% of the market in 2023. High per-sample costs, despite 20% reductions through improved kits, continue to limit uptake by smaller institutions. Edman Degradation still holds 46% of technology usage, despite mass spectrometry offering 30–40% higher throughput. Services remain concentrated in a few contract research organizations, leaving 40% of potential demand underserved. Developing economies still face infrastructure gaps, with Asia-Pacific capturing only 20% of share. Regulatory validation requirements extending up to several years also constrain services expansion.

OPPORTUNITY

"Growth in personalized medicines."

Biotherapeutics applications accounted for 56% of the market, reflecting rising use of personalized protein data in drug development. Academic and research institutes contributed 45% of sequencing demand, further supporting personalized healthcare projects. Single-molecule sequencing accounted for 15% of new installations in 2024, allowing personalized proteome analysis. Asia-Pacific share increased from 15% in 2020 to nearly 20% in 2024, boosted by government investments. U.S. federal funding for proteomics rose 30% from 2020 to 2023. Antibody sequencing services now account for over 70% of contract workflows in mass spectrometry, creating new revenue potential in personalized therapeutics.

CHALLENGE

"Rising costs and expenditures."

Mass spectrometers, with 54% of adoption, demand upfront costs exceeding USD 500,000, deterring 30% of small research labs. Edman Degradation reagents contribute up to 20% of product costs. Maintenance and training add 10–15% to operating expenses. Services represent only 19% of market share, as cost margins discourage broad adoption. In emerging economies, limited funding has restricted Asia-Pacific share below 20% until recently. Academic labs, representing 45% of usage, face budgetary limits when upgrading to high-cost platforms. High expenditure remains a barrier to widespread adoption of protein sequencing technologies.

Protein Sequencing Market Segmentation

The Protein Sequencing Market Segmentation is structured by type and application. By type, Edman Degradation and Mass Spectrometry dominate global share. By application, the market includes Academic Institutes & Research Centers, Pharmaceutical & Biotechnology Companies, and Others.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Edman Degradation: Edman Degradation represented 46% of the technology market in 2025. This traditional approach is widely used in academic institutions, which accounted for 45% of global sequencing demand. Approximately 40% of U.S. sequencing labs still use Edman technology, mainly for small peptide sequencing and educational purposes.

The Edman Degradation segment of the Protein Sequencing market is valued at USD 480.12 million in 2025, holding 44.45% share, projected to reach USD 595.32 million by 2034, growing at a CAGR of 2.46%.

Top 5 Major Dominant Countries in the Edman Degradation Segment

• United States: Market size USD 152.17 million in 2025 with 31.7% share, expected to reach USD 182.55 million by 2034 at a CAGR of 2.05% driven by research and pharma demand.
• Germany: Market size USD 48.66 million in 2025 with 10.1% share, expected to expand to USD 62.12 million by 2034, recording CAGR of 2.75% supported by strong academic infrastructure.
• Japan: Market size USD 44.25 million in 2025 with 9.2% share, rising to USD 58.36 million by 2034, advancing at a CAGR of 3.02% due to growing precision medicine adoption.
• United Kingdom: Market size USD 36.42 million in 2025 with 7.6% share, reaching USD 46.85 million by 2034, CAGR of 2.84% attributed to pharmaceutical collaborations.
• China: Market size USD 34.05 million in 2025 with 7.1% share, projected to USD 47.21 million by 2034, CAGR of 3.60% owing to rapid expansion of biotech research hubs.

Mass Spectrometry: Mass spectrometry accounted for 54% of global sequencing adoption in 2025. Pharmaceutical and biotechnology companies, with 50% of end-user share, lead demand for this technology. In North America, over 60% of new instrument installations in 2023 were mass spectrometers. Asia-Pacific installations rose from 15% in 2020 to 25% in 2024.

The Mass Spectrometry segment of the Protein Sequencing market is estimated at USD 600.05 million in 2025, holding 55.55% share, projected to reach USD 823.50 million by 2034, growing at a CAGR of 3.52%.

Top 5 Major Dominant Countries in the Mass Spectrometry Segment

• United States: Market size USD 201.05 million in 2025 with 33.5% share, rising to USD 279.42 million by 2034, CAGR of 3.69% driven by antibody sequencing and proteomics.
• China: Market size USD 89.65 million in 2025 with 14.9% share, forecast to USD 129.75 million by 2034, CAGR of 4.14% supported by rapid industrial and medical adoption.
• Germany: Market size USD 62.45 million in 2025 with 10.4% share, set to reach USD 84.26 million by 2034, CAGR of 3.41% boosted by pharma-biotech collaborations.
• Japan: Market size USD 55.82 million in 2025 with 9.3% share, expanding to USD 76.48 million by 2034, CAGR of 3.57% propelled by high-throughput proteomics.
• India: Market size USD 44.13 million in 2025 with 7.3% share, projected to USD 63.26 million by 2034, CAGR of 4.05% fueled by government funding and biotech startups.

BY APPLICATION

Academic Institutes & Research Centers: Academic institutions accounted for 45% of global sequencing demand. Approximately 15% of instruments in Europe and North America were installed in universities and public research centers.

The Academic Institutes & Research Centers segment is valued at USD 350.65 million in 2025 with 32.45% share, forecasted to USD 441.22 million by 2034, growing at a CAGR of 2.64%.

Top 5 Major Dominant Countries in the Academic Institutes & Research Centers Application

• United States: Market size USD 112.65 million in 2025 with 32.1% share, rising to USD 139.21 million by 2034, CAGR of 2.40% driven by academic grants and funding.
• Germany: Market size USD 39.74 million in 2025 with 11.3% share, projected at USD 51.20 million by 2034, CAGR of 2.83% supported by strong university research.
• Japan: Market size USD 33.72 million in 2025 with 9.6% share, reaching USD 43.56 million by 2034, CAGR of 2.95% attributed to growing proteomics research projects.
• United Kingdom: Market size USD 29.56 million in 2025 with 8.4% share, expanding to USD 38.21 million by 2034, CAGR of 2.93% driven by public research funding.
• China: Market size USD 28.53 million in 2025 with 8.1% share, expected to USD 39.04 million by 2034, CAGR of 3.49% with heavy state funding in research.

Pharmaceutical & Biotechnology Companies: This application segment represented 50% of global share in 2023. Biotherapeutics accounted for 56% of overall applications. In North America, pharmaceutical and biotech firms invested nearly USD 280 million in sequencing products in 2024.

The Pharmaceutical & Biotechnology Companies segment is valued at USD 635.50 million in 2025 with 58.84% share, projected to USD 833.20 million by 2034, growing at a CAGR of 3.03%.

Top 5 Major Dominant Countries in the Pharmaceutical & Biotechnology Companies Application

• United States: Market size USD 211.36 million in 2025 with 33.2% share, growing to USD 272.10 million by 2034, CAGR of 2.86% led by antibody drug pipelines.
• China: Market size USD 98.12 million in 2025 with 15.4% share, rising to USD 135.54 million by 2034, CAGR of 3.66% from expanding pharma-biotech industries.
• Germany: Market size USD 63.55 million in 2025 with 10% share, projected to USD 82.05 million by 2034, CAGR of 2.96% with strong pharma research alliances.
• Japan: Market size USD 58.23 million in 2025 with 9.2% share, forecast to USD 75.45 million by 2034, CAGR of 3.01% through biotech innovation.
• India: Market size USD 48.20 million in 2025 with 7.6% share, set to USD 66.50 million by 2034, CAGR of 3.53% backed by rapid CRO outsourcing growth.

Others: The Others segment held 5% share, comprising forensic labs, environmental testing, and veterinary use. Spending reached approximately USD 100 million globally in 2024. Mass spectrometry dominated this segment with 70% share.

The Others application segment is valued at USD 94.02 million in 2025 with 8.71% share, expected to reach USD 144.40 million by 2034, growing at a CAGR of 4.94%.

Top 5 Major Dominant Countries in the Others Application

• United States: Market size USD 29.15 million in 2025 with 31% share, rising to USD 41.20 million by 2034, CAGR of 3.95% fueled by forensic and environmental labs.
• China: Market size USD 15.55 million in 2025 with 16.5% share, forecast to USD 25.30 million by 2034, CAGR of 5.59% due to rapid diagnostic adoption.
• Germany: Market size USD 9.82 million in 2025 with 10.4% share, projected to USD 14.40 million by 2034, CAGR of 4.44% supported by industrial testing.
• Japan: Market size USD 8.62 million in 2025 with 9.2% share, reaching USD 12.94 million by 2034, CAGR of 4.44% with niche proteomics usage.
• India: Market size USD 7.84 million in 2025 with 8.3% share, growing to USD 13.05 million by 2034, CAGR of 5.73% driven by food safety applications.

Protein Sequencing Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America held 36% of the global market in 2023. The U.S. contributed 25% of total global value, equal to USD 514 million. Canada accounted for USD 80 million and Mexico USD 40 million. Products dominated with 81% share, services 19%. Biotherapeutics represented 56% of usage. Mass spectrometry accounted for 60% of installations. Federal funding for proteomics rose 30% from 2020 to 2023. Genetic testing volume increased from 1,000 to 3,000 cases between 2021 and 2022.

The North America Protein Sequencing Market is valued at USD 388.46 million in 2025 with 35.9% share, expected to expand to USD 505.30 million by 2034, growing at a CAGR of 3.03%.

North America - Major Dominant Countries in the Protein Sequencing Market

• United States: Market size USD 301.80 million in 2025 with 77.6% regional share, projected to USD 388.40 million by 2034, CAGR of 3.01% leading globally in adoption.
• Canada: Market size USD 42.15 million in 2025 with 10.8% share, expected to reach USD 55.50 million by 2034, CAGR of 3.11% driven by proteomics projects.
• Mexico: Market size USD 24.50 million in 2025 with 6.3% share, forecast to USD 32.85 million by 2034, CAGR of 3.27% through expanding biotech sector.
• Brazil: Market size USD 12.65 million in 2025 with 3.2% share, growing to USD 17.10 million by 2034, CAGR of 3.44% supported by academic demand.
• Argentina: Market size USD 7.36 million in 2025 with 1.9% share, projected at USD 11.45 million by 2034, CAGR of 4.97% with increasing clinical usage.

Europe

Europe contributed 22–25% of global share. Germany, UK, and France made up 60% of the region’s total. Western Europe held USD 250 million, while Eastern Europe contributed USD 30 million. Product share was 80%, services 20%. Biotherapeutics represented 50% of demand. Academic labs expanded sequencing activity by 20% between 2021 and 2023. Mass spectrometry made up 55% of installations. Regulatory timelines extended adoption by 6–12 months, but collaborations increased sequencing sample volumes by 30%.

The Europe Protein Sequencing Market is valued at USD 294.36 million in 2025 with 27.25% share, projected to reach USD 384.70 million by 2034, CAGR of 3.04%.

Europe - Major Dominant Countries in the Protein Sequencing Market

• Germany: Market size USD 83.50 million in 2025 with 28.4% regional share, reaching USD 108.20 million by 2034, CAGR of 3.01% driven by pharma-biotech partnerships.
• United Kingdom: Market size USD 62.12 million in 2025 with 21.1% share, projected to USD 80.20 million by 2034, CAGR of 2.95% with strong research activity.
• France: Market size USD 55.42 million in 2025 with 18.8% share, forecast to USD 72.40 million by 2034, CAGR of 3.01% supported by academic funding.
• Italy: Market size USD 47.85 million in 2025 with 16.3% share, expected to USD 62.10 million by 2034, CAGR of 2.99% linked to biotech sector expansion.
• Spain: Market size USD 45.47 million in 2025 with 15.4% share, forecast to USD 61.80 million by 2034, CAGR of 3.46% driven by proteomics adoption.

Asia-Pacific

Asia-Pacific share grew from 15% in 2020 to nearly 20% by 2024, equaling USD 400 million in value. China accounted for USD 150 million, India USD 80 million, Japan USD 70 million, and South Korea and Southeast Asia together USD 100 million. Mass spectrometry installations rose from 15% of global capacity in 2020 to 25% in 2024. Academic demand increased 40% in China and 35% in India from 2020 to 2023. Pharmaceutical procurement increased 20% annually across the region.

The Asia Protein Sequencing Market is estimated at USD 293.27 million in 2025 with 27.15% share, projected to USD 392.25 million by 2034, CAGR of 3.26%.

Asia - Major Dominant Countries in the Protein Sequencing Market

• China: Market size USD 135.05 million in 2025 with 46% regional share, rising to USD 181.22 million by 2034, CAGR of 3.34% as biotech accelerates adoption.
• Japan: Market size USD 76.45 million in 2025 with 26% share, projected to USD 102.65 million by 2034, CAGR of 3.35% backed by proteomics research funding.
• India: Market size USD 45.55 million in 2025 with 15.5% share, expected to USD 64.35 million by 2034, CAGR of 3.88% with CRO outsourcing growth.
• South Korea: Market size USD 23.35 million in 2025 with 8% share, forecast to USD 31.65 million by 2034, CAGR of 3.35% with pharma collaborations.
• Australia: Market size USD 12.87 million in 2025 with 4.5% share, growing to USD 16.38 million by 2034, CAGR of 2.72% driven by clinical proteomics.

Middle East & Africa

This region held 5–7% of global market share, equaling about USD 100 million in 2024. Saudi Arabia and UAE together accounted for USD 30 million, South Africa USD 25 million, Egypt USD 15 million, and the rest of the region USD 30 million. Products held 75% of share, services 25%. Academic institutes drove 50% of demand, pharmaceutical companies 45%, others 5%. Mass spectrometry and Edman technologies were equally split at 50% each. Sequencing adoption grew 15% between 2021 and 2023 due to increased regional collaborations.

The Middle East and Africa Protein Sequencing Market is valued at USD 104.08 million in 2025 with 9.63% share, expected to reach USD 136.57 million by 2034, growing at a CAGR of 3.07%.

Middle East and Africa - Major Dominant Countries in the Protein Sequencing Market

• Saudi Arabia: Market size USD 31.45 million in 2025 with 30.2% share, projected to USD 41.25 million by 2034, CAGR of 3.01% from clinical adoption.
• UAE: Market size USD 22.35 million in 2025 with 21.5% share, forecast to USD 29.85 million by 2034, CAGR of 3.18% led by biotech funding.
• South Africa: Market size USD 20.15 million in 2025 with 19.4% share, rising to USD 26.85 million by 2034, CAGR of 3.20% from academic growth.
• Egypt: Market size USD 17.35 million in 2025 with 16.6% share, expected to USD 22.95 million by 2034, CAGR of 3.14% due to rising lab installations.
• Israel: Market size USD 12.78 million in 2025 with 12.3% share, growing to USD 15.85 million by 2034, CAGR of 2.48% linked to R&D activity.

List of Top Protein Sequencing Companies

• SGS
• Proteome Factory
• Bioinformatics Solutions
• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• Rapid Novor Inc.
• Waters
• Selvita
• Agilent Technologies, Inc.
• Charles River Laboratories

Top Two Companies With Highest Share

• Thermo Fisher Scientific Inc. held approximately 15–18% of global market share.
• Agilent Technologies, Inc. held approximately 10–12% of global market share.

Investment Analysis and Opportunities

Investments in the Protein Sequencing Market are concentrated in products, which account for 81% of total value, compared to services at 19%. North America attracted 36% of global investment, while Asia-Pacific rose to nearly 20%. U.S. investment reached USD 514 million in 2024, academic institutes represented USD 230 million, and pharmaceutical firms USD 280 million. In Asia-Pacific, China accounted for USD 150 million, India USD 80 million, and Japan USD 70 million. Middle East & Africa contributed USD 100 million, led by Saudi Arabia and UAE. Single-molecule sequencing systems represented 12–15% of new investment, reflecting innovation opportunities. Kits with 20% improved amino acid detection rates opened new commercial prospects. Government funding increased by 30% in the U.S. and 35% in India, signaling rising public-private collaborations.

New Product Development

The Protein Sequencing Market has seen rapid product innovations. In 2024, sequencing kits improved amino acid detection by 20% while cutting per-sample costs. Mass spectrometry systems launched with throughput increases of 30–40% over prior versions. Single-molecule sequencing platforms represented 12–15% of new purchases. Software advancements improved antibody sequencing coverage by 25%. Automated Edman systems introduced reagent efficiencies, lowering usage by 15%. Hybrid sequencing platforms allowed dual sequencing modes, doubling efficiency. Compact mass spectrometry units reduced instrument size by 20%. Lab-on-chip devices processed up to 100 peptides per chip. Cloud-based bioinformatics solutions improved post-translational modification detection by 18%.

Five Recent Developments

• Launch of new sequencing kits in 2024 improved detection by 20% and reduced cost per sample.
• S. genetic testing rose from 1,000 to 3,000 cases between 2021 and 2022.
• A major acquisition in 2023 added advanced proteomics platforms valued at USD 3.1 billion.
• Asia-Pacific mass spectrometry installations grew from 15% of global capacity in 2020 to 25% in 2024.
• North America maintained 36% of global market share in 2023, with 81% product share and 56% biotherapeutics application.

Report Coverage of Protein Sequencing Market

The Protein Sequencing Market Report covers global size, segmentation, technology mix, applications, and regional distribution. In 2024, the market was USD 2.04 billion, led by North America with 36% share, Europe with 22–25%, Asia-Pacific with 20%, and Middle East & Africa with 5–7%. The U.S. contributed USD 514 million, Canada USD 80 million, Mexico USD 40 million, China USD 150 million, India USD 80 million, Japan USD 70 million, Saudi Arabia and UAE USD 30 million. Technology segmentation shows mass spectrometry at 54% and Edman Degradation at 46%. Products accounted for 81% of share, services 19%. Applications split into biotherapeutics at 56%, academic research 45%, and others 5%. End-user distribution favored pharmaceutical and biotech at 50%, academic institutes 45%, others 5%. Competitive analysis showed Thermo Fisher with 15–18% and Agilent with 10–12% market share. Trends included single-molecule sequencing adoption at 12–15%, improved kit efficiency by 20%, and higher mass spectrometry throughput by 30–40%. Regional funding increases of 30–35% supported new opportunities. The coverage emphasizes investment, innovation, application expansion, and strategic positioning for stakeholders.

Protein Sequencing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1113.44 Million in 2026
Market Size Value By	USD 1462.52 Million by 2035
Growth Rate	CAGR of 3.08% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Edman Degradation Mass Spectrometry By Application : Academic Institutes & Research Centers Pharmaceutical & Biotechnology Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample